Please login to the form below

Not currently logged in
Email:
Password:

Dutch biotech Mucosis promotes Thomas Johnston to CEO

He succeeds Govert Schouten who leaves to found an internet start-up

Dutch biotech Mucosis Thomas JohnstonThomas Johnston has been promoted to CEO of Mucosis to take over from Govert Schouten, who is leaving the Dutch clinical-stage biotech to found an internet start-up.

Johnston joined Mucosis last May as chief business officer from the clinical biopharmaceutical company Novavax, where he served as vice president of strategy.

Prior to that he served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with companies such as Comcast, Microsoft, and Schlumberger.

John Lambert, chairman of the Mucosis board of directors, said: "Tom has more than 15 years of leadership experience in the biotech and other industries and has been an invaluable member of our executive management team.

“Given Tom's substantial commercial experience and familiarity with the Company, we are confident he is the right person to lead Mucosis as we execute our strategy and further advance the development and commercialisation of the Mimopath platform including our RSV vaccine candidate."

During the last 12 months Mucosis has completed a clinical proof of concept study in human influenza for Mimopath and advanced respiratory syncytial virus (RSV) candidate SynGEM into pre-clinical studies.

19th September 2012

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....